New pharmaceutical R&D spending trends and biotech funding environment (drives software license demand)
Large enterprise contract wins or renewals with top-20 pharma companies
Regulatory adoption of in-silico modeling (FDA guidance expanding use cases for simulation tools)
Acquisition integration success and return to positive operating margins
moderate - Pharmaceutical R&D spending is relatively recession-resistant as drug development timelines span years and regulatory requirements don't change with economic cycles. However, biotech funding (venture capital, IPOs) is highly cyclical and affects smaller clients' ability to purchase software. Large pharma clients provide stability, but emerging biotech represents growth opportunity that contracts during downturns.
Rising interest rates negatively impact the biotech funding environment, reducing venture capital availability and IPO activity for smaller pharmaceutical companies that represent growth customers. Higher rates also pressure valuation multiples for unprofitable software companies. The company's zero debt means no direct financing cost impact, but customer financing conditions matter significantly.
AI/machine learning disruption from tech giants (Google DeepMind, Nvidia) entering drug discovery with competing computational platforms
Regulatory risk if FDA/EMA reduce acceptance of in-silico modeling or require more extensive clinical validation
Consolidation in pharmaceutical industry reducing total number of potential enterprise clients
growth - Small-cap healthcare technology play historically attracted growth investors betting on pharmaceutical digitalization trends and recurring software revenue models. However, the -66% one-year return and profitability collapse have likely shifted the shareholder base toward distressed/turnaround investors or those betting on operational restructuring. High volatility and small market cap ($200M) limit institutional ownership.
Trend
+4.2% vs SMA 50 · -14.3% vs SMA 200
Momentum
Accumulation pattern present — more buying days than selling over the past 20 sessions. Volume conditions support gradual price improvement.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
ANALYST ESTIMATES
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $79.0M $78.1M–$80.0M | — | $1.03 | — | ±2% | Moderate3 |
FY2026(current) | $81.7M $81.3M–$82.3M | ▲ +3.5% | $0.86 | ▼ -16.7% | ±4% | High5 |
FY2027 | $86.5M $85.4M–$87.9M | ▲ +5.9% | $0.92 | ▲ +6.9% | ±2% | High5 |
INSTITUTIONAL OWNERSHIP
SLP News
About
Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. With its subsidiaries, Cognigen, DILIsym Services, and Lixoft, we offer solutions which bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. The company's technology is licensed and applied by major pharmaceutical, biotechnology, chemical, consumer goods companies and regulatory agencies worldwide.
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
SLP◀ | $13.34 | +0.00% | $270M | — | — | — | 1500 |
| $66.13 | -5.07% | $13.0B | — | +12626.1% | -14525.8% | 1500 | |
| $94.92 | -3.79% | $12.6B | — | +3288.2% | -4239.0% | 1500 | |
| $523.69 | -3.00% | $12.1B | — | +43205.3% | -3008.0% | 1500 | |
| $227.72 | -1.96% | $11.7B | — | +6554.5% | -2868.8% | 1500 | |
| $57.90 | -0.86% | $11.2B | 50.3 | +1459.3% | 147.7% | 1500 | |
| $76.67 | -3.79% | $10.8B | — | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -2.64% | — | 50.3 | +398824.8% | -4085.6% | 1500 |